{"entity":{"id":"nct06987500","kind":"trial","name":"A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment","aka":[],"tldr":"A phase 1/2 trial of XNW29016 in advanced solid tumours, run by Evopoint Biosciences Inc., now recruiting.","summary":"A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment is a phase 1/2 interventional study registered as NCT06987500 by Evopoint Biosciences Inc., with 132 participants planned, started 2025-04-11 and due to reach its primary completion in 2027-02-14. Interventions recorded: XNW29016.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06987500","url":"https://clinicaltrials.gov/study/NCT06987500"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["evopoint-biosciences"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06987500","phase":"1/2","setting":"A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of XNW29016 Tablets in Advanced Solid Tumors With Failed Standard Treatment","sponsor":"Evopoint Biosciences Inc.","enrolled":132,"outcomes":[]},"route":"/trials/nct06987500/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"evopoint-biosciences","kind":"company","name":"Evopoint Biosciences","route":"/companies/evopoint-biosciences/"}]}}